Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

References

• Babar ZU, Francis S. Identifying priority medicines policy issues for New Zealand: a general inductive study. BMJ Open 2014;4(5):e004415
   PubMed Web of Science ®Google Scholar
• Drews J. Drug discovery: a historical perspective. Science 2000;287(5460):1960-4
   PubMed Web of Science ®Google Scholar
• Lichtenberg F. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009. Health Policy Technol 2014;3:36-58
   Web of Science ®Google Scholar
• Thomas Hofmarcher, Bengt Jönsson, Nils Wilking. Access to high-quality oncology care across europe. Available from: www.ihe.se/getfile.aspx?id=23042014
   Google Scholar
• Jönsson B, Ramsey S, Wilking N. Cost effectiveness in practice and its effect on clinical outcomes. J Cancer Policy 2014;2:12-21
   Google Scholar
• Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014;312(6):593-4
   PubMed Web of Science ®Google Scholar
• News and analysis. Costly cancer care. JAMA 2014;312(6):591
   Google Scholar
• Kmietowicz Z. NICE says drug for metastatic breast cancer is unaffordable for NHS. BMJ 2014;348:g2888
   Google Scholar
• Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy 2013;11(1):1-3
   PubMedGoogle Scholar
• Garattini S, Bertele V, Godman B, et al. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol 2008;64(12):1137-8
   PubMed Web of Science ®Google Scholar
• Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health Policy 2014;116(2-3):137-46
   PubMed Web of Science ®Google Scholar
• Godman B, Petzold M, Bennett K, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?: findings from across Europe and their implications. BMC Med 2014;12(1):98
   PubMed Web of Science ®Google Scholar
• Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol 2014;5:109
   PubMed Web of Science ®Google Scholar
• Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312(6):631-40
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14
   PubMed Web of Science ®Google Scholar
• Kaplan W, Wirtz V, Mantel-Teeuwisse A, et al. Priority Medicines for Europe and the World 2013 Update Report. 2013. Available from: www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=1
   Google Scholar
• Lam B, Henry L, Younossi Z. Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert Rev Clin Pharmacol 2014;7(5):555-66
   PubMed Web of Science ®Google Scholar
• Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009;27(13):2111-13
   PubMed Web of Science ®Google Scholar
• Godman B, Finlayson AE, Cheema PK, et al. Personalizing health care: feasibility and future implications. BMC Med 2013;11:179
   PubMed Web of Science ®Google Scholar
• O’Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA 2013;310(13):1343-4
   PubMed Web of Science ®Google Scholar
• Evaluate Pharma. Surveying Tomorrow’s BioPharma Landscape. The NASDAQ Biotech Index Up Close 2012. Available from: http://info.evaluatepharma.com/rs/evaluatepharmaltd/images/EvaluatePharma_NBI_Up_Close_2012.pdf
   Google Scholar
• The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121(22):4439-42
   PubMed Web of Science ®Google Scholar
• Cohen P, Felix A. Are payers treating orphan drugs differently? J Market Access Health Policy 2014.2:23513. Available from: http://dx.doi.org/10.3402/jmahp.v2
   Google Scholar
• Rodwin MA. Introduction: institutional corruption and the pharmaceutical policy. J Law Med Ethics 2013;41(3):544-52
   PubMedGoogle Scholar
• Ozieranski P, McKee M, King L. Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? Health Econ Policy Law 2012;7(2):175-95
   PubMedGoogle Scholar
• Mello MM, Abiola S, Colgrove J. Pharmaceutical companies’ role in state vaccination policymaking: the case of human papillomavirus vaccination. Am J Public Health 2012;102(5):893-8
   PubMedGoogle Scholar
• Luo J, Oliveira MA, Ramos MB, et al. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011. BMC Public Health 2014;14:367
   PubMed Web of Science ®Google Scholar
• Lexchin J, Kohler JC. The danger of imperfect regulation: oxyContin use in the United States and Canada. Int J Risk Saf Med 2011;23(4):233-40
   PubMedGoogle Scholar
• Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med 2010;7(10):e1000352
   PubMed Web of Science ®Google Scholar
• Baumgärtel C, Godman B, Malmström R, et al. What lessons can be learned from the launch of generic clopidogrel? GaBI J 2012;1(2):58-68
   Google Scholar
• Light DW, Lexchin J, Darrow JJ. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013;41(3):590-600
   PubMed Web of Science ®Google Scholar
• Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 2011;343:d5621
   PubMedGoogle Scholar
• Davis C, Abraham J. Is there a cure for corporate crime in the drug industry? BMJ 2013;346:f755
   PubMed Web of Science ®Google Scholar
• Gagnon MA. Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health. J Law Med Ethics 2013;41(3):571-80
   PubMed Web of Science ®Google Scholar
• Fisk M, Feeley J, Voreacos D. J&J Said to Agree to $2.2 Billion Drug Marketing Accord. 2012. Available from: wwwbloombergcom/news/2012-06-11/j-j-said-to-pay-2-2-billion-to-end-risperdal-sales-probe.html
   Google Scholar
• Department of Justice (US). Department of Justice Settlement agreement between United States and AstraZeneca. 2010. Available from: www.justice.gov/usao/pae/Pharma-Device/astrazeneca_settlementagreement.pdf
   Google Scholar
• Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res 2008;8(4):357-71
   PubMedGoogle Scholar
• New drugs and indications in 2011. France is better focused on patients’ interests after the Mediator scandal, but stagnation elsewhere. Prescrire Int 2012;21(126):106-7
   PubMedGoogle Scholar
• Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum Pretium–the just price. J Clin Oncol 2013;31(28):3600-4
   PubMed Web of Science ®Google Scholar
• Scottish Medicines Consortium. sofosbuvir 400mg tablet (Sovaldi®). SMC No. (964/14). Available from: www.scottishmedicines.org.uk/files/advice/M__Scottish_Medicine_Consortium_Web_Data_Audit_advice_Advice_by_Year_2014_No.6_-_June_2014_sofosbuvir__Sovaldi__FINAL_May_2014_for_website.pdf
   Google Scholar
• Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013;4:39
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 2005;23(5 Suppl 39):S195-200
   Google Scholar
• Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol 2014. [Epub ahead of print]
   Google Scholar
• Gorokhovich LE, Chalkidou K, Shankar R. Improving access to innovative medicines in emerging markets: evidence and diplomacy as alternatives to the unsustainable status quo. J Health Diplomacy 2013;1(1):1-19
   Google Scholar
• Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. Health Policy 2011;100(2-3):134-43
   PubMed Web of Science ®Google Scholar
• Sheppard A. Generic Medicines: Essential contributors to the long-term health of society - Sector sustainability challenges in Europe. Available from: www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf
   Google Scholar
• Babar ZU, Kan SW, Scahill S. Interventions promoting the acceptance and uptake of generic medicines: a narrative review of the literature. Health Policy 2014;117(3):285-96
   PubMedGoogle Scholar
• Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012;106(3):211-24
   PubMed Web of Science ®Google Scholar
• Moon JC, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol 2014;5:219
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106
   PubMed Web of Science ®Google Scholar
• Hassali MA, Alrasheedy A, McLachlan A, et al. The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use. Saudi Med J 2014. [In Press] Available from: http://ac.els-cdn.com/S131901641300128X/1-s2.0-SX-main.pdf?_tid=e8de644e-f7d0-11e3-925d-00000aacb35f&acdnat=1403196418_7987f3f513f2ef578bb8a8372b612f1a
   Google Scholar
• Godman B, Acurcio F, Guerra Junior AA, et al. Initiatives among authorities to improve the quality and efficiency of prescribing and the implications. J Pharma Care Health Sys 2014;1(3):1-15
   Google Scholar
• Garner S, Littlejohns P. Do NICE’s recommendations for disinvestment add up? BMJ 2011;343:349-51
   Google Scholar
• Pichetti S, Sorasith C, Sermet C. Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998-2010. Health Policy 2011;102(2-3):159-69
   PubMedGoogle Scholar
• Elshaug AG, Watt AM, Mundy L, Willis CD. Over 150 potentially low-value health care practices: an Australian study. Med J Aust 2012;197(10):556-60
   PubMedGoogle Scholar
• Nuti S, Vainieri M, Bonini A. Disinvestment for re-allocation: a process to identify priorities in healthcare. Health Policy 2010;95(2-3):137-43
   PubMedGoogle Scholar
• Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard. PLoS One 2012;7(8):e42701
   PubMed Web of Science ®Google Scholar
• Silverman E. How Italy Saves Money: Paying For Off-Label Use of Avastin. Available from: http://blogs.wsj.com/pharmalot/2014/06/11/how-italy-saves-money-paying-for-off-label-use-of-avastin/
   Google Scholar
• Jolly D. Italy Fines Novartis and Roche in Collusion Case. 2014. Available from: www.nytimes.com/2014/03/06/business/international/italy-fines-novartis-and-roche-in-collusion-case.html?_r=0
   Google Scholar
• Vitry AI, Shin NH, Vitre P. Assessment of the therapeutic value of new medicines marketed in Australia. J Pharm Policy Pract 2013;6:2
   PubMedGoogle Scholar
• Van Wilder P, Dupont A. Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome? Value Health 2008;11(4):784-7
   PubMedGoogle Scholar
• Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ 2012;345:e4348
   PubMed Web of Science ®Google Scholar
• Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005;4(1):78-84
   PubMedGoogle Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101(15):1044-8
   PubMedGoogle Scholar
• Barbui C, Violante A, Garattini S. Does placebo help establish equivalence in trials of new antidepressants? Eur Psychiatry 2000;15(4):268-73
   PubMedGoogle Scholar
• Garattini S, Bertele V, Banzi R. Placebo? no thanks, it might be bad for me!. Eur J Clin Pharmacol 2013;69(3):711-14
   PubMed Web of Science ®Google Scholar
• Henshall C, Sansom L, Eichler H-G, et al. Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: what are they looking for, and how and why does this differ from what regulators require? Ther Innov Regul Sci 2014;48(3):341-6
   PubMedGoogle Scholar
• Mullard A. 2011 FDA drug approvals. Nat Reviews Drug Discov 2012;11(2):91-4
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol 2014;15(3):e112-e8
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, de Vries E, Verweij J, Sullivan R. Dispelling the myths around cancer care delivery: it’s not all about costs. J Cancer Policy 2014;2:22-9
   Google Scholar
• Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer. J Med Chem 2014;57(16):6949-64
   PubMed Web of Science ®Google Scholar
• Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Ado-trastuzumab Emtansine: A HER2-positive targeted antibody-drug conjugate. Ann Pharmacother 2014;48(11):1484-93
   PubMedGoogle Scholar
• NCPE. Trastuzumab emtansine (Kadcyla®) - reimbursement not recommended. Available from: http://www.ncpe.ie/wp-content/uploads/2013/10/Trastuzumab-emtansine-summary.pdf
   Google Scholar
• Duerden M. Affording expensive new drugs. Prescriber 2014;8
   Google Scholar
• Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ 2006;333(7578):1118-20
   PubMed Web of Science ®Google Scholar
• Brogan DM, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Global Health 2013;9:58
   PubMed Web of Science ®Google Scholar
• Roland D. Why is Roche’s new breast cancer drug so expensive? Available from: www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11021272/Why-is-Roches-new-breast-cancer-drug-so-expensive.html
   Google Scholar
• NICE News and Features. Pressure grows on Roche to lower breast cancer drug price. Available from: https://www.nice.org.uk/News/Article/pressure-grows-on-roche-to-lower-breast-cancer-drug-price2014
   Google Scholar
• Roche. Annual Report. Available from: www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCEQFjAA&url=http%3A%2F%2Fwww.roche.com%2Fgb13e.pdf&ei=JA0EVJqrNdPZavLDgJAG&usg=AFQjCNF-VWJBImTwunCSU50eqb-OtDfvRA&bvm=bv.74115972,d.d2s2013
   Google Scholar
• Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012;1(6):527-38
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9(1):65-83
   PubMedGoogle Scholar
• Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82
   PubMed Web of Science ®Google Scholar
• Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy 2013;11(1):79-82
   PubMedGoogle Scholar
• Gentile I, Borgia G. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. Evid Based Med 2014
   Google Scholar
• Yau AH, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review. Can J Gastroenterol Hepatol 2014;28(8):445-51
   PubMedGoogle Scholar
• Zawawi M. Malaysian Society of Gastroenterology and Hepatology. MANAGEMENT OF HEPATITIS C 2014. Available from: www.msgh.org.my/resources/managementhepatitisc.htm
   Google Scholar
• MSF Access Campaign (Access Campaign). Diagnosis and Treatment of Hepatitis C: a technical landscape. 2014. Available from: www.msfaccess.org/sites/default/files/MSF_assets/HepC/Docs/MSF%20HCV%landscape.pdf
   Google Scholar
• Appleby J. Who Should Get Pricey Hepatitis C Drugs? 2014. Available from: www.kaiserhealthnews.org/stories/2014/may/05/sovaldi-who-should-get-pricey-drug.aspx?utm_campaign=khn%3a+daily+health+policy+report&utm_source=hs_email&utm_medium=email&utm_content=12687408&_hsenc=p2anqtz-80dq0zkyq2cmdwwi2qfttaz29txfzqm-fnpvl7bczz8ps8h4pu0ssjarxaqkjchr867noeij3y-hi6msp3-9uc2gfpyw&_hsmi=12687408
   Google Scholar
• Heitz D. Harvoni takes the sting out of hepatitis c treatment. healthline news. 2014. Available from: www.healthline.com/health-news/harvoni-takes-sting-out-of-hepatitis-c-treatment-102614
   Google Scholar
• Beasley D. UPDATE 2-Gilead third-quarter Sovaldi sales dip, but net profit triples: Reuters. 2014. Available from: www.reuters.com/article/2014/10/28/gilead-sciences-results-idUSL1N0SN2NY20141028
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 6th edition. Brussels, Belgium. Available from: www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf
   Google Scholar
• Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 2013;44(1):47-58
   PubMedGoogle Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383(9922):1068-83
   PubMed Web of Science ®Google Scholar
• IMS. Spending levels in 2017 on medicine for specific disease areas will differ significantly between developed and pharmerging markets. Spending by Therapy Area in 2017. The Global Use of Medicines: Outlook through 2017 Report by the IMS Institute for Healthcare Informatics. 2014. Available from: www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%Institute/Reports/Global_Use_of_Meds_Outlook_2017/Spending_Therapy_Area_.pdf
   Google Scholar
• IMS. The global use of medicines: outlook through 2016 - Report by IMS Institute for Healthcare Informatics. Available from: www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf
   Google Scholar
• NICE. The Management of Type 2 Diabetes: NICE Clinical Guideline 87. National Institute for Health and Care Excellence; London: 2009
   Google Scholar
• Editorial. Towards better patient care: drugs to avoid. Rev Prescrire 2013;33(352):138-42
   Google Scholar
• Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329(5):304-9
   PubMed Web of Science ®Google Scholar
• The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25(12):2165-71
   PubMed Web of Science ®Google Scholar
• Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res 2012;12(1):23-9
   PubMed Web of Science ®Google Scholar
• Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis 2014;9:62
   PubMed Web of Science ®Google Scholar
• Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis 2013;8:198
   PubMed Web of Science ®Google Scholar
• Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol 2011;71(4):488-96
   PubMed Web of Science ®Google Scholar
• National Commissioning Board. Clinical Commissioning Policy: ivacaftor for Cystic Fibrosis - Reference : NHSCB/A01/P/b. Available from: www.england.nhs.uk/wp-content/uploads/2013/04/a01-p-b.pdf
   Google Scholar
• Joppi R, Bertele V, Garattini S. Orphan drug development is not taking off. Br J Clin Pharmacol 2009;67(5):494-502
   PubMedGoogle Scholar
• Gemeinsamer Bundesausschuss. Questions and Answers about the Procedure - Are orphan drugs exempt from early assessment? Available from: www.english.g-ba.de/benefitassessment/information/faq/#32014
   Google Scholar
• Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013;69(4):1009-24
   PubMed Web of Science ®Google Scholar
• Process on Corporate Social Responsibility in the Field of Pharmaceuticals - Platform on Access to Medicines in Europe. Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP). 2012. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/orphans_conlusions_en.pdf
   Google Scholar
• Braunlin E, Rosenfeld H, Kampmann C, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(R)) therapy. J Inherit Metab Dis 2013;36(2):385-94
   PubMed Web of Science ®Google Scholar
• Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science 2012;335(6069):645
   PubMed Web of Science ®Google Scholar
• Cohen D, Raftery J. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ 2014;348:g1445
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Kalydeco - Key Facts. 2014. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002494/smops/Positive/human_smop_000701.jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human
   Google Scholar
• FiercePharma. Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations. Available from: www.fiercepharma.com/press-releases/vertex-receives-european-approval-kalydecotm-ivacaftor-eight-non-g551d-gati
   Google Scholar
• Scottish Medicines Consortium. Ivacaftor 150mg film-coated tablets (Kalydeco®) SMC No. (827/12) - Resubmission 2013. Available from: www.scottishmedicines.org.uk/files/advice/ivacaftor__Kalydeco__Resubmission_FINAL_May_2013.doc_for_website.pdf
   Google Scholar
• PharmaDispatch; Copays and listings the focus of Senate Estimates 2014. Available from: www.cysticfibrosis.org.au/media/wysiwyg/CF-Australia/Advocacy/Kalydeco/PharmaDispatch.pdf
   Google Scholar
• Guerra AAJr, Cesar CC, Cherchiglia ML, et al. Cyclosporine versus tacrolimus in immunosuppressive maintenance regimens in renal transplants in Brazil: survival analysis from 2000 to 2004. Ann Pharmacother 2010;44(1):192-201
   PubMed Web of Science ®Google Scholar
• Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother 2014;48(10):1258-68
   PubMed Web of Science ®Google Scholar
• Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014;349:g4670
   PubMed Web of Science ®Google Scholar
• Phend C. Monitoring, dose adjustment for pradaxa? 2014. Available from: www.medpagetoday.com/Cardiology/Arrhythmias/46901
   Google Scholar
• Iannone F, Gremese E, Atzeni F, et al. Long-term retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012;39(6):1179-84
   PubMed Web of Science ®Google Scholar
• Raaschou P, Simard JF, Holmqvist M, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013;346:f1939
   PubMed Web of Science ®Google Scholar
• Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis. Int J Clin Pharmacol Ther 2012;50(12):867-72
   PubMedGoogle Scholar
• Spatz I, McGee N. Health Policy Brief: Specialty Pharmaceuticals. Health Affairs 2013;1-4
   Google Scholar
• Khan S, Moore JE, Gomes T, et al. The ontario drug policy research network: bridging the gap between research and drug policy. Health policy (Amsterdam, Netherlands) 2014
   PubMedGoogle Scholar
• Gustafsson LL, Wettermark B, Godman B, et al. The ’wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108(4):224-33
   PubMed Web of Science ®Google Scholar
• Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013;69(Suppl 1):73-8
   PubMed Web of Science ®Google Scholar
• Kardakis T, Tomson G, Wettermark B, et al. The establishment and expansion of an innovative centre for rational pharmacotherapy-determinants and challenges. Int J Health Plann Manage 2013
   PubMedGoogle Scholar
• Wonder M. What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry? Expert Rev Pharmacoecon Outcomes Res 2014;14(4):465-7
   PubMed Web of Science ®Google Scholar
• Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 2012;12(4):439-41
   PubMed Web of Science ®Google Scholar
• Joppi R, Dematte L, Menti AM, et al. The Italian Horizon Scanning Project. Eur J Clin Pharmacol 2009;65(8):775-81
   PubMedGoogle Scholar
• Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United kingdom. Int J Technol Assess Health Care 2012;28(3):308-14
   PubMedGoogle Scholar
• Nachtnebel A, Geiger-Gritsch S, Hintringer K, Wild C. Scanning the horizon: development and implementation of an early awareness system for anticancer drugs in Austria. Health Policy 2012;104(1):1-11
   PubMedGoogle Scholar
• Wild C, Simpson S, Douw K, et al. Information service on new and emerging health technologies: identification and prioritization processes for a European union-wide newsletter. Int J Technol Assess Health Care 2009;25(Suppl 2):48-55
   PubMedGoogle Scholar
• Wettermark B, Persson ME, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res 2010;10:128
   PubMed Web of Science ®Google Scholar
• Joppi R, Cinconze E, Mezzalira L, et al. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med 2013;24(4):318-23
   PubMed Web of Science ®Google Scholar
• Troncoso A, Diogene E. Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. Eur J Clin Pharmacol 2014;70(2):249-50
   PubMedGoogle Scholar
• Fritz JM, Cleland J. Effectiveness versus efficacy: more than a debate over language. J Orthop Sports Phys Ther 2003;33(4):163-5
   PubMed Web of Science ®Google Scholar
• Wonder M, Backhouse ME, Hornby E. Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia. Value Health 2013;16(6):1067-73
   PubMedGoogle Scholar
• Gauld R. Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary. Pharmacoeconomics 2014;32(10):937-42
   PubMedGoogle Scholar
• Babar Z-U-D, Vitry A. Differences in Australian and New Zealand medicines funding policies. Aust Health Rev 2014;38(1):6-15
   PubMedGoogle Scholar
• Metcalfe S, Grocott R, Rasiah D. Comment on "Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following its 20th Anniversary" : Clarification from PHARMAC: PHARMAC Takes No Particular Distributive Approach (Utilitarian or Otherwise). Pharmaco Economics 2014;32(10):1031-3
   PubMedGoogle Scholar
• Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Z Med J 2011;124(1346):12-28
   PubMedGoogle Scholar
• Kolasa K, Schubert S, Manca A, Hermanowski T. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy 2011;102(2-3):145-51
   PubMedGoogle Scholar
• Moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: a critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 2011;7:39
   PubMed Web of Science ®Google Scholar
• Knowledge Ecology International. Resurrecting the Ghost of Høsbjør Past: Global Fund seeks to establish global framework on tiered pricing enforced by WTO rules. Available at: http://keionline.org/node/1979
   Google Scholar
• Baker B. Industry-led tiered-pricing or country-led, real equitable access – the global fund’s task force proposal get worse instead of better. Available from: http://infojustice.org/wp-content/uploads/2014/03/Baker-Global-Fund-Tiered-Pricing-03282014.pdf
   Google Scholar
• Vogler S, Zimmermann N, Habl C, Mazag J. The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost effectiveness and resource allocation : C/E 2013;11(1):15
   PubMedGoogle Scholar
• DeRidder R, Adriaens C, Kleinermans D, et al. Mechanism of coordinated access to orphan drugs. Orphanet J Rare Dis 2012;7(Suppl 2):A24
   PubMedGoogle Scholar
• Garattini S. Time to revisit the orphan drug law. Eur J Clin Pharmacol 2012;68(2):113
   PubMed Web of Science ®Google Scholar
• Schiff GD, Galanter WL, Duhig J, et al. A prescription for improving drug formulary decision making. PLoS Med 2012;9(5):1-7
   PubMed Web of Science ®Google Scholar
• Lima-Dellamora ED, Caetano R, Gustafsson LL, et al. An Analytical Framework for Assessing Drug and Therapeutics Committee Structure and Work Processes in Tertiary Brazilian Hospitals. Basic Clin Pharmacol Toxicol 2014;115(3):268-76
   PubMedGoogle Scholar
• Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001;323(7309):378-81
   PubMedGoogle Scholar
• Trindade E. [Adoption of new technologies by health services: the challenge of analyzing relevant factors]. Cad Saude Publica 2008;24(5):951-64
   PubMedGoogle Scholar
• Van Wilder PB, Bormans VV, Dupont AG. Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: current practices and outcome agreement between Belgium, the Netherlands and France. Eur J Clin Pharmacol 2013;69(12):2037-43
   PubMedGoogle Scholar
• Rosenberg-Yunger ZR, Thorsteinsdottir H, Daar AS, Martin DK. Stakeholder involvement in expensive drug recommendation decisions: an international perspective. Health Policy 2012;105(2-3):226-35
   PubMed Web of Science ®Google Scholar
• Canadian Partnership Against Cancer and pCODR. How cancer drug funding decisions are made. 2012. Available from: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-funding-tutorial.pdf
   Google Scholar
• European Commission. Platform on access to medicines in Europe 2014. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/process_on_corporate_responsibility/platform_access/index_en.htm#h2-4
   Google Scholar
• Wettermark B, Godman B, Eriksson C, et al. Einführung neuer Arzneimittel in europäische Gesundheitssysteme (Introduction of new medicines into European healthcare systems). GGW 2010;10(3):24-34
   Google Scholar
• Cumming J, Mays N, Daube J. How New Zealand has contained expenditure on drugs. BMJ 2010;340:c2441
   Google Scholar
• PHARMAC. Prescription for Pharmacoeconomic Analysis - Methods for cost-utility analysis 2012. Available from: www.pharmac.health.nz/assets/pfpa-final.pdf
   Google Scholar
• Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008;26(7):537-50
   PubMedGoogle Scholar
• Simoens S, De Bruyn K, Miranda J, et al. Measures to enhance ARB prescribing efficiency in Belgium following generic losartan: impact and implications for the future. J Pharmaceutical Health Services Res 2013;4:173-81
   Google Scholar
• Jagodzińska-Kalinowska K, Ofierska-Sujkowska G, Matusewicz W. The influence of recommendations related to antineoplastic drugs issued by agency for health technology assessment in poland (AOTM) in 2013 for the reimbursement decisions. Abstract Booklet - HTAi Annual Meeting 2014 2014:122. Available from: www.htai2014.org/temp/201461669967/HTAI_AbstractVolume_web2.pdf
   Google Scholar
• Godman B, Persson M, Miranda J, et al. Changes in the utilization of venlafaxine after the introduction of generics in Sweden. Appl Health Econ Health Policy 2013;11(4):383-93
   PubMedGoogle Scholar
• Efpia. improving patient access to innovative medicines - the framework in which differentiated pricing may offer a solution 2014. Available from: www.efpia.eu/uploads/Modules/Documents/pac-280214-ai6-a1-differentiated-pricing-position-paper-final.pdf
   Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12(1):125-30
   PubMed Web of Science ®Google Scholar
• Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res 2009;9(6):569-81
   PubMedGoogle Scholar
• Norman C, Zarrinkoub R, Hasselstrom J, et al. Potential savings without compromising the quality of care. Int J Clin Pract 2009;63(9):1320-6
   PubMed Web of Science ®Google Scholar
• Godman B, Campbell S, Suh HS, et al. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J Health Tech Assess 2013;1:27-42
   Google Scholar